Xiangqiu Chen

Dr. Xiangqiu Chen

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2023 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
DSDonglin Sun
Donglin Sun
JGJing Guo
Jing Guo
WLWeifei Liang
Weifei Liang
YCYangxiao Chen
Yangxiao Chen
XCXiangqiu Chen
Xiangqiu Chen
LWLi Wang
Li Wang
Purpose. We examined whether anlotinib can attenuate folic acid-induced and unilateral ureteral obstruction-induced renal fibrosis and explored the underlying antifibrotic mechanism. Materials and Methods. We have evaluated the effects of anlotinib on folic acid-induced and unilateral ureteral obstruction-induced renal fibrosis in mice through in vivo experiments of unilateral ureteral obstruction or folic acid-induced interstitial fibrosis and in vitro models of transforming growth factor-β1 induced HK-2 human renal proximal tubule cells. Serum renal function parameters and inflammatory cytokine levels were measured, and histological changes of renal injury and fibrosis were analyzed by HE staining and immunohistochemistry. Immunohistochemistry and Western blotting were used to determine the mechanism of action of anlotinib in ameliorating renal fibrosis. Results. Anlotinib improved proteinuria and reduced renal impairment in folic acid-induced mouse models of renal fibrosis. Anlotinib reduced tubular injury, deposition of tubular extracellular matrix, and expression of alpha-smooth muscle actin, transforming growth factor-β1, and cytosolic inflammatory factors compared with controls. Conclusions. Anlotinib ameliorated renal function, improved extracellular matrix deposition, reduced protein levels of epithelial-mesenchymal transition markers, and decreased cellular inflammatory factors. Anlotinib reduced renal injury and fibrosis by inhibiting the transforming growth factor-β1 signaling pathway through AKT and ERK channels.

3 January 2024 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
DSDonglin Sun
Donglin Sun
JGJing Guo
Jing Guo
WLWeifei Liang
Weifei Liang
YCYangxiao Chen
Yangxiao Chen
SWShuqi Wei
Shuqi Wei
XCXiangqiu Chen
Xiangqiu Chen

15 March 2025 in Life Sciences
Verified
Journal Article
Closed access
WLWeifei Liang
Weifei Liang
HWHaoyu Wu
Haoyu Wu
QLQishan Long
Qishan Long
HLHong Lin
Hong Lin
XLXiaoyu Lv
Xiaoyu Lv
DSDonglin Sun
Donglin Sun

17 January 2026 in iMetaMed
Verified
Journal Article
Open access
WLWeifei Liang
Weifei Liang
XCXiangqiu Chen
Xiangqiu Chen
TWTao Wu
Tao Wu
XZXichun Zheng
Xichun Zheng
SZShaohua Zeng
Shaohua Zeng
DSDonglin Sun
Donglin Sun
Chronic kidney disease (CKD) is a major global health issue. Kidney fibrosis is a key mechanism leading to end‐stage renal disease. Senescence of renal tubular epithelial cells (RTECs) and the senescence‐associated secretory phenotype (SASP) factors they release are crucial in kidney fibrosis progression. While isorhamnetin, the active component of Astragalus membranaceus , has demonstrated promise in combating senescence/aging and fibrosis, its precise mechanism of action remains poorly understood. This study aims to elucidate the mechanisms through which isorhamnetin mitigates RTEC senescence and kidney fibrosis, specifically by modulating the interleukin‐6 (IL‐6) signaling pathway. The findings indicate that isorhamnetin significantly attenuates kidney fibrosis in aging mice, inhibiting IL‐6 secretion from senescent RTECs and reducing its accumulation in kidney tissues. In vitro analyses further revealed that isorhamnetin disrupted IL‐6 signaling by competitively binding to the IL‐6 receptor, thereby slowing RTEC senescence. Additional investigations demonstrated that isorhamnetin's inhibition of IL‐6 secretion from senescent RTECs impacted macrophage M2 polarization and the transformation of fibroblasts into myofibroblasts, thus decelerating the progression of kidney fibrosis. This study highlights the critical role of isorhamnetin in alleviating RTEC senescence and kidney fibrosis through the suppression of the IL‐6 signaling pathway, underscoring its potential for clinical application in CKD treatment.